Reproductive biology and the breakfast delicacy scrapple have much in common, including the difficulty in easily defining what's in it and the certainty that many items have contributed to the final product. For the purposes of this commentary, reproductive biology is defined as the scientific study of conception, pregnancy, disorders that impair fertility and complicate pregnancy and fertility control in humans and animals.
The science of reproduction lies at the nexus of key issues facing humanity worldwide, including treatments that regulate fertility, the safety and success of human reproduction, the spread and consequences of sexually transmitted diseases, and the connection between the reproductive process and the quality and duration of life. As behavior and lifestyle are major determinants of reproductive choices such as pregnancy, its outcome and the risk of sexually acquired pathogens, behavioral science must be considered as a major component of the scholarship that underpins reproductive biology.
Advances in the reproductive sciences have transformed our lives and produced scientific revolutions. The development of oral contraceptives and assisted reproduction technology (ART) has given humans the potential to influence fertility, which is arguably among the most important achievements of the last century. The discovery of the mechanism of peptide and steroid hormone action ushered in the modern era of the study of gene regulation and an associated blooming of new therapeutic agents. Cloning techniques and embryonic stem cell biology have origins in the reproductive sciences.
Most importantly, the science of reproduction is about the future-that is, population dynamics and future needs for food and resources. Moreover, antenatal events are increasingly being recognized as determinants of postnatal health and disease burden in the developing and developed world. Additionally, scientific advances in reproductive biology have been a catalyst for considerable research and debate in the field of bioethics and have shaped this field. They have also increased public awareness of the interface between science and personal and societal rights and responsibilities. Those interested in the modern history of reproductive biology will find an authoritative book on the topic, Disciplining Reproduction by Adele Clark 1 , informative in its treatment of how the discipline developed in the US and the UK and how scientific, social and political forces shaped it.
The papers selected by leaders in the discipline of reproductive science as the most important recent advances in reproductive biology, highlighted in this issue of Nature Medicine, represent an interesting lens through which to view the field. They reflect shifting trends in research, with an increasingly stronger embrace of studies of pregnancy complications and the impact of environmental factors on fetal development, including epigenetic alterations, and a growing emphasis on fertility preservation.
Considering these shifting research trends, it is of interest to ask whether funding trends have followed a similar direction.
Research funding and priority setting
There are many urgent research questions to address across the biomedical sciences, and limited federal research dollars are available to meet the need. In allocating scarce resources, the 27 institutes and centers that are part of the National Institutes of Health (NIH) face a difficult and often sensitive task, where they must weigh the importance of health concerns, the state of the science, and the potential for new discoveries. Much of the NIH funding is distributed to scientists on the basis of investigator-initiated proposals that are reviewed by outside experts, where the scientific quality of the proposal is paramount.
NIH institutes also set aside funding to target specific areas of research where additional work is needed to fill science gaps and develop specific fields. In reviewing scientific priorities, the NIH and other federal agencies must also fulfill mandates from Congress, and consider input from constituencies such as research scientists, clinicians who apply research results, and organized advocacy groups. In the case of reproductive biology, a diverse advocacy system includes a number of research societies and patient special interest groupsthe Andrology Society, the American Society for Reproductive Medicine, the Society for the Study of Reproduction, the Society for Gynecological Investigation, the Society for Women's Health Research-and diseasespecific organizations such as the March of Dimes, Resolve (an infertility-focused organization), the Endometriosis Society and the Pre-eclampsia Society, among others.
The needs for research in reproductive sciences as identified by a broad community of interested parties have been outlined in multiple reports from the Institute of Medicine (IOM). These address a range of issues, including research in academic departments of obstetrics and gynecology 2 , contraceptive development 3, 4 and preterm birth 5 . However, the size of the need, and the complexity of cO m m e n ta rY the priority-setting process, creates a natural tension between different research areas or disease-specific interests. For example, autism advocates point to the high number of children diagnosed with an autism spectrum disorder; the March of Dimes, which is in a campaign to reduce prematurity, highlights the rising prevalence of premature birth, and the Pre-eclampsia Society focuses on a disorder that affects 7% of pregnancies and is not well understood. Balancing this tension is a challenge for the NIH institutes that support reproductive biology research.
The unmet research needs identified in the IOM reports as well as in white papers from various societies lay out key arenas for investments that will sustain the field and attract new blood. William Crowley, a reproductive biologist at Massachusetts General Hospital, has a favorite aphorism: "money is chemotactic." That is an immutable principle, as evidenced by what might be called the golden era of reproductive biology, circa 1960-1985, when a number of large foundations, such as the Rockefeller Foundation, the Ford Foundation and the Mellon Foundation, in addition to the NIH, were providing substantial support for research and training opportunities 6 in the reproductive sciences, and when industry was making major investments to develop an array of fertility-regulating devices and drugs. These investments attracted scientists and physicians to the field. Unfortunately, these foundations no longer provide substantial support in this research area, and industry support for reproductive research is under pressure, affected by consolidation and interest in other research areas 7, 8 .
The NIH, particularly the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), provides the lion's share of support for research and research training activities in reproduction (as defined above) within the US federal government (and perhaps the world). In fiscal year 2007, the NIH support for infertility research totaled $51 million, and $314 million was spent on contraception and reproduction research 9 . Of the latter amount, roughly 12% was devoted to contraception research by the NICHD (data provided by the NICHD office of Science Policy, Analysis and Communication). Perhaps the most ambitious study ever undertaken with substantial relevance to reproductive processes is the National Children's Study. Led by the NICHD, this project, projected to cost more than $3 billion, will follow 100,000 women of different racial and ethnic backgrounds in locations across the country before and after conception, as well as their offspring up until the age of 21. The complex and detailed study could address important issues in preeclampsia, preterm birth, environmental exposures and the developmental origins of adult disease.
NIH is not the only federal stakeholder in the reproductive sciences. Modern reproductive biology in the US, the UK and Australia can trace its heritage back to animal science. The study of domestic animal reproduction brought forth key conceptual advances from the study of altered fertility and fecundity in domestic species. Accordingly, the US Department of Agriculture (USDA) sponsors research in reproductive biology 10, 11 . The basic reproductive biology research supported by the USDA in the past has taught us about gonadal function, assisted reproduction and the mechanisms of seasonal control of reproduction, which has informed our knowledge of biological rhythms. The value of the perspective of animal reproduction should therefore not be discounted. After all, according to a recent article, "the missions of USDA and NIH are inextricably linked as the health, well-being and fertility of domestic species underpin the availability and affordability of high quality, nutritious food, which contributes to health maintenance and the prevention of chronic diseases in humans" 12 .
The March of Dimes offers a competitive grant program with a current emphasis on prematurity. The Burroughs-Wellcome Fund is also partnering with the March of Dimes to offer a new grant program on preterm birth. These are important initiatives that add needed dollars to the search for methods to prevent a problem estimated to cost the US about $26 billion per year 5 . The current tumult in the financial markets has reduced the endowments of these organizations, which will likely negatively impact funding of this initiative.
The 
Programs for translational science
These days, an often used term in the scientific repertoire is 'translational research'. Some think it started with the establishment of the NIH Roadmap at the turn of the millennium. The truth is that the NIH has always supported translational research, if we define that research as a continuum that encompasses all aspects of the bidirectional knowledge transfer between animal models and humans. For example, application of information from rodent species to nonhuman primates and vice versa is part of that translational continuum. The ultimate goal of translational research in reproduction, however we might define it, is to improve human reproductive health. This is no easy task for one program to accomplish. As such, the NICHD provides support for several programs that, when taken together, provide an infrastructure for the conduct of translational research in reproduction. These include the Specialized Cooperative Centers Program in Reproduction and Infertility Research (SCCPIR), the Contraceptive Development Centers Program, the Reproductive Medicine Network (RMN), the Contraceptive Clinical Trials Network and the Maternal-Fetal Medicine Network (Box 1). These multicenter programs have produced the evidence base for the current approaches for predicting risk of preterm birth and the optimal infertility treatments. For example, the recent randomized clinical trial conducted by the RMN comparing clomiphene and metformin, two drugs widely used in the treatment of anovulatory infertility associated with polycystic ovary syndrome, was based on observational studies supported in part by the SCCPIR.
One of the most important links in the continuum of translational research efforts is the nonhuman primate. Nonhuman primate research has been primarily funded by the NIH National Center for Research Resources through the National Primate Research Program Centers. However, in recent years, the emphasis on HIV research has diverted funds, scientific interest and training in primate research away from reproductive biology, which used to be a traditional strong suit of several of the National Primate Research Centers. The late Ernst Knobil, a founding father of primate reproductive neuroendocrinology, spoke of "the tyranny of the rat." He was reflecting on the fact that although there are similarities between rodents and humans, human reproduction is not well modeled by laboratory species. The limited availability of primates and the cost of using them in research represent a considerable bottleneck in translational research.
The next generation-training and career development
Here is a chicken-and-egg problem to consider when thinking about funding for a scientific discipline such as reproductive biology. Scientists are market-makers, and the quantity and quality of the scientific workforce create a demand for funding and public awareness of the potential benefit of their work to society. The density and activity of a scientific discipline in turn affect the flux of predoctoral and postdoctoral trainees into the field. No one has a handle on how many reproductive scientists are needed to address the unmet needs in research. Their number is therefore determined by available funding for training grants and cyclical trends in the workforce.
Greater focus is being placed on the physician investigator, and a number of career development mechanisms are in place to address the pipeline of this group, including the NICHD's Reproductive Scientist Development Training of graduate students and postdoctoral fellows is supported by an array of institutional T32 predoctoral and postdoctoral training grants. Currently, 47 predoctoral and 61 postdoctoral trainees are supported by T32 grants administered by the NICHD's Reproductive Sciences Branch. The Fogarty International Center supports training grants in population science for developing countries, which include research training in reproductive biology.
The Burroughs-Wellcome Fund also provides support in partnership with NICHD for the Frontiers in Reproduction course; a six-week laboratory and lecture course held at the Marine Biological Laboratories in Woods Hole, Massachusetts for individuals interested in acquiring the knowledge and laboratory skills necessary to pursue a research career in the reproductive sciences. The impact of the early years of this course has received a favorable evaluation 14 .
Although the number of training and career development programs for reproductive biologists-both physician-investigators and doctoral scientists-seems respectable, it is only one slice of the pizza. We cannot ignore the fact that the attrition for investigators in transition is high. Is it higher in reproductive biology than in other disciplines? We don't know, and it would be of interest to have that statistic. Given the current 20-year time frame from the start of predoctoral training through the first independent research award, it is essential that we understand the forensics of the training process and determinants of success. There are some reports 13, 14 that give us a starting point to explore this question.
Consultations with the Ouija board
So, what does the future hold? We see a number of crucial issues facing the reproductive sciences that may achieve some traction for increased research funding. The National Children's Study mentioned above should provide important new information about the effect of environment and ethnicity and race on reproductive outcomesinformation that will address key questionsrelating to the role of prepregnancy health and fetal development on adult health. This should feed new hypotheses.
The dichotomy between falling birth rates in developed countries and rising birth rates in the poorest countries will split the 'personalities' of funding agencies. The impact of ART on offspring is an increasingly important issue, given the number of births worldwide resulting from ART. The first wave of ART offspring are just entering their second and third decades of life. The clinical procedures have undergone continuous evolution, and long-term monitoring of ART children, which has mostly been done in Europe, has not been a focus in the US, and there is a need for more vigilance, as it was only a few years ago that evidence for rare epigenetic disorders associated with ART surfaced. Furthermore, it is not clear that those disorders are all due to ART. A recent study 15 suggests that infertility per se influences pregnancy outcome, not the procedures used to ameliorate it, thereby setting off the alarm that we may need to refocus attention to treating the underlying infertility problem.
Conversely, as recently reported by the Population Reference Bureau 16 , efforts to reduce birth rates in the world's most impoverished countries have gone into stall mode. As this reality sinks in, research in contraception may see a little more sunshine. Finally, the uniqueness of germ cells, the complexity of mechanisms that regulate the process of reproduction, the essential role that procreation has in the preservation of the human species and the considerable impact of fertility disorders on quality of life should remain a draw for talented investigators and a cause for funding agencies and foundations to support.
